Keith Regnante, Chief Financial Officer at Keros Therapeutics, Inc. (KROS), sold 80,000 shares at $47.25 ($3.7M) on 2023-06-09, disclosed to the SEC on 2023-06-12.
Scheduled sale ($3.7M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $47.66 | 17,301 | $825K | 22.1% |
| 2 | $47.66 | 17,301 | $825K | 22.1% |
| 3 | $48.65 | 2,699 | $131K | 3.5% |
| 4 | $48.65 | 2,699 | $131K | 3.5% |
| 5 | $45.03 | 15,993 | $720K | 19.3% |
| 6 | $45.03 | 15,993 |
| $720K |
| 19.3% |
| 7 | $46.46 | 1,428 | $66K | 1.8% |
| 8 | $46.46 | 1,428 | $66K | 1.8% |
| 9 | $47.25 | 2,579 | $122K | 3.3% |
| 10 | $47.25 | 2,579 | $122K | 3.3% |
| Total | $46.61 avg | 80,000 | $3.7M | 100% |
| Filing → |
| KROS | SELL | 2024-01-08 | $1.8M | — | Filing → |
| WVE | SELL | 2019-02-21 | $48K | — | Filing → |
| WVE | SELL | 2018-09-26 | $1.6M | — | Filing → |